Primary source: Inspections and Compliance
The Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System was authorized by the FDA effective August 25, 2026.
This device is the first in the world to continuously monitor both glucose and ketone levels, providing crucial data for managing diabetes and preventing critical complications such as diabetic ketoacidosis.
Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.
The FDA has granted marketing authorization for the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System, a wearable device that allows individuals aged 2 years and older with diabetes to monitor both blood sugar and ketone levels simultaneously. This device continuously checks these levels every minute and sends real-time alerts to users, enhancing early detection of diabetic ketoacidosis.
What changed: The Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System was authorized by the FDA effective August 25, 2026.
Why it matters: This device is the first in the world to continuously monitor both glucose and ketone levels, providing crucial data for managing diabetes and preventing critical complications such as diabetic ketoacidosis.
Practical implication: Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.
Published from the regulator source ingestion pipeline after PV impact triage.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
Regulatory intelligence teams must update workflows to exclude clove oil as an anesthetic for fish and ensure compliance with the guidance, including awareness of approved alternatives.
Clinical investigations must now include justification for DDM selection and ensure that DHTs are verified and validated to support their intended clinical role.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
